Cargando…
Gemcitabine for the treatment of advanced nonsmall cell lung cancer
Gemcitabine is a pyrimidine nucleoside antimetabolite agent which is active in several human malignancies, including nonsmall cell lung cancer (NSCLC). Because of its acceptable toxicity profile, with myelosuppression being the most common adverse event, gemcitabine can be safely combined with a num...
Autores principales: | Toschi, Luca, Cappuzzo, Federico |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886326/ https://www.ncbi.nlm.nih.gov/pubmed/20616908 |
Ejemplares similares
-
First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients
por: Li, Ying, et al.
Publicado: (2014) -
TNNC1 Reduced Gemcitabine Sensitivity of Nonsmall-Cell Lung Cancer by Increasing Autophagy
por: Ye, Xian, et al.
Publicado: (2020) -
Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
por: Glatzer, Markus, et al.
Publicado: (2016) -
Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer
por: Gridelli, Cesare, et al.
Publicado: (2011) -
New developments in locally advanced nonsmall cell lung cancer
por: Huber, Rudolf M., et al.
Publicado: (2021)